Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739024 · ClinicalTrials.gov registry record · Phase 2
A Study of a Melatonin Receptor Agonist to Prevent Migraine
A Phase 2 study, sponsored by Swedish Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00739024 is a Phase 2 study that was terminated before completion, run by Swedish Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00739024, a Phase 2 study, was terminated before completion, sponsored by Swedish Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S. Food and Drug Administration (FDA) for insomnia (trouble sleeping); however; ramelteon has not been approved for the prevention of migraines.
Interventions
- DRUG Placebo
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739024
The ClinicalTrials.gov registry entry for NCT00739024 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00739024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739024 about?
NCT00739024 is a clinical study titled "A Study of a Melatonin Receptor Agonist to Prevent Migraine". The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S. Food and Drug Administration (FDA) for insomnia (trouble sleeping); however; r...
What is the current status of trial NCT00739024?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00739024?
The interventions under investigation include: Placebo (DRUG), Ramelteon (DRUG).
Who is sponsoring clinical trial NCT00739024?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.